TechnoMark News

At present, there is no vaccine against this virus still, researchers and experts are focusing on understanding the correlates of defensive immunity for fetus and information about few major components of maternal immune response required for prevention of transplacental transmission. This infection is majorly prevalent in the newborns in the United States. The progress of the ongoing COVID-19 pandemic, worldwide has substantially impact several healthcare domains and other areas of research activities. Research institutions are forced to take crucial precautions during the current lockdown status in several major economies. Though most research and manufacturing companies are facing shutdown positions and delays in most important tasks, few companies are continuing their studies and being active for vaccine research. Major Key Players of the Cytomegalovirus (CMV) Vaccines Market are: Merck's, AlphaVax, Inc., and Moderna, Inc. are some companies working on CMV immunizations. ...

Cytomegalovirus (CMV) also known as HCMV, or Human Herpesvirus 5 (HHV-5) is the virus most commonly transmitted to a developing fetus. It is a common virus that infects people of all ages. According to the CDC, over half of adults by age 40 have been infected with CMV. Most people infected with CMV show no signs or symptoms. Whereas when a baby is born with cytomegalovirus (CMV) infection, it is called congenital CMV. Each year, approximately 5,000 infants in the U.S. may develop permanent problems due to CMV, some of the severe problems, includes deafness, blindness, and mental retardation. Furthermore, the global prevalence of congenital cytomegalovirus is said to be 0.3 - 2.0%. The Institute of Medicine (IOM) of the National Academy of Sciences, has designated CMV as a "highest priority" category for vaccine development, citing the years of life and disability that could be saved. Increasing incidences & prevalence of CMV and rising investments towards the developm...